

BIOCRYST PHARMACEUTICALS INC
Form SC 13G/A
February 14, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

BioCryst Pharmaceuticals, Inc.
(Name of Issuer)

Common Stock, par value \$.01
(Title of Class of Securities)

09058V103
(CUSIP Number)

December 31, 2012
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“*Act*”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. **09058V103 13G** Page 2 of 7 Pages

1. Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
RA Capital Management, LLC

Check the Appropriate Box if
2. a Member of a Group (See Instructions)
(a)
(b)

3. SEC Use Only

Citizenship or
4. Place of Organization
Massachusetts

5. Sole Voting Power **0**

Number of Shares Beneficially Owned by Each Reporting Person With
6. Shared Voting Power **0**
7. Sole Dispositive Power **0**

8. Shared Dispositive Power **0**

9. Aggregate Amount Beneficially Owned by Each Reporting Person
0

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)
0.0%

12. Type of Reporting Person (See Instructions)
IA

CUSIP No. **09058V103** 13G Page **3** of **7** Pages

Names of
1. Reporting
Persons.
I.R.S.
Identification
Nos. of above
persons (entities
only).
Peter Kolchinsky

Check the
Appropriate Box
2. if a Member of a
Group (See
Instructions)
(a) "
(b) "

3. SEC Use Only

Citizenship
or
4. Place of
United States
of
Organization

5. Sole Voting Power **0**

Number of
Shares
Beneficially
Owned by
Each Reporting
Person With

6. Shared Voting Power **0**

7. Sole Dispositive Power **0**

8. Shared Dispositive Power **0**

9. Aggregate Amount Beneficially Owned by Each Reporting Person
0

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)
0.0%

12. Type of Reporting Person (See Instructions)
IN

CUSIP No. **09058V103 13G** Page 4 of 7 Pages

Names of
1. Reporting
Persons.
I.R.S.
Identification
Nos. of above
persons
(entities
only).
**RA Capital
Healthcare
Fund, L.P.**

Check the
Appropriate
Box if a
2. Member of a
Group (See
Instructions)
(a) "
(b) "

3. SEC Use
Only

Citizenship
or
4. Place of
Incorporation
of
Organization
Delaware

5. Sole Voting Power **0**

Number of
Shares
Beneficially
Owned by
Each Reporting
Person With

6. Shared Voting Power **0**

7. Sole Dispositive Power **0**

8. Shared Dispositive Power **0**

9. Aggregate Amount Beneficially Owned by Each Reporting Person
0

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

11. Percent of Class Represented by Amount in Row (9)
0.0%

12. Type of Reporting Person (See Instructions)
PN

CUSIP No. **09058V103** Page 5 of 7

Item 1.

- (a) **Name of Issuer:** BioCryst Pharmaceuticals, Inc. (the “Issuer”).
- (b) **Address of the Issuer’s Principal Executive Offices:** 4505 Emperor Blvd., Suite 200, Durham, North Carolina 22703.

Item 2.

- (a) **Name of Person Filing:** This joint statement on Schedule 13G is being filed by Peter Kolchinsky, RA Capital Management, LLC, and RA Capital Healthcare Fund, L.P., who are collectively referred to herein as the “Reporting Persons.” Mr. Kolchinsky (the “Manager”) is the manager of RA Capital Management, LLC (“Capital”), which is the investment adviser and sole general partner of RA Capital Healthcare Fund, L.P. (“Fund”) and serves as the investment adviser to a separate discretionary account. The Reporting Persons have entered into a Joint Filing Agreement, dated as of the date hereof, a copy of which is filed with this Schedule 13G as Exhibit 1 (which is incorporated herein by reference), pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k) under the Act.
- (b) **Address of Principal Business Office:** The principal business office of the Reporting Persons with respect to the shares reported hereunder is 20 Park Plaza, Suite 1200, Boston, MA 02116.
- (c) **Citizenship:** Capital is a Massachusetts limited liability company. The Fund is a Delaware limited partnership. The Manager is a United States citizen.
- (d) **Title and Class of Securities:** Common stock (“Common Stock”).
- (e) **CUSIP Number:** 09058V103.

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4. Ownership:

The Reporting Persons, as of the date of this filing, report the following beneficial ownership:

- | | Amount |
|---|--------|
| (a) Beneficially Owned: | 0 |
| (b) Percent of Class: | 0.0% |
| (c) to which such person has: | |
| (i) sole power to vote or to direct the vote: | 0 |
| (ii) shared power to vote or to direct the vote: | 0 |
| (iii) sole power to dispose or to direct the disposition of: | 0 |
| (iv) shared power to dispose or to direct the disposition of: | 0 |

CUSIP No. **09058V103** Page 6 of 7

Item 5. Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

Item 6. Ownership of More than Five Percent on Behalf of Another Person:

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

Not applicable.

Item 8. Identification and Classification of Members of the Group:

Not applicable.

Item 9. Notice of Dissolution of Group:

Not applicable.

Item 10. Certification:

By signing below I hereby certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. **09058V103** Page 7 of 7

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2013

RA CAPITAL HEALTHCARE FUND, L.P.

By: RA Capital Management, LLC
General Partner

By: /s/ Peter Kolchinsky
Peter Kolchinsky
Manager

RA CAPITAL MANAGEMENT, LLC

By: /s/ Peter Kolchinsky
Peter Kolchinsky
Manager

PETER KOLCHINSKY

/s/ Peter Kolchinsky

Exhibit 1

JOINT FILING AGREEMENT

Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agrees, as of February 14, 2013, that only one statement containing the information required by Schedule 13G, and each amendment thereto, need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of BioCryst Pharmaceuticals, Inc., and such statement to which this Joint Filing Agreement is attached as Exhibit 1 is filed on behalf of each of the undersigned.

RA CAPITAL
HEALTHCARE FUND,
L.P.

By: RA Capital
Management, LLC
General Partner

By: /s/ Peter Kolchinsky
Peter Kolchinsky
Manager

RA CAPITAL
MANAGEMENT, LLC

By: /s/ Peter Kolchinsky
Peter Kolchinsky
Manager

PETER KOLCHINSKY

/s/ Peter Kolchinsky